Literature DB >> 10506654

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies.

F Notka1, C Stahl-Hennig, U Dittmer, H Wolf, R Wagner.   

Abstract

Recombinant, insect cell derived SIV Pr56(gag) virus-like particles (VLPs) have been modified either by inserting HIV-1 Gp160 derived peptides into the Pr56(gag) precursor or by integrating the complete HIV-1 gp120 in the particle membrane. To investigate the protective efficacy of these particulate antigens, rhesus macaques were immunized with VLPs both adjuvant-free or adsorbed to alum. In addition, recombinant Semliki Forest viruses (SFV) expressing proteins corresponding to the VLP constructs were established and administered as live vaccines in combination with particulate antigens. Vaccination induced specific humoral responses irrespective of the immunization regimen. However, in contrast to Pr56(gag)-specific antibodies, Env-specific antibody titers could not be increased by booster immunizations in this study. Cell-mediated immune responses were detected following vaccination with VLP-preparations as well as recombinant SFVs. A tendency towards stimulating both enhanced cell mediated as well as humoral immune responses was observed following priming with recombinant SFVs. Upon challenge with SHIV-4 all vaccinated monkeys became infected. However, animals, that were vaccinated with VLPs presenting the complete gp120, managed to clear virus faster than nonimmunized controls. The observed virus elimination significantly correlated with an anamnestic antibody response and an accelerated appearance of neutralizing antibodies postchallenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506654     DOI: 10.1016/s0264-410x(99)00200-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Authors:  Lei Zhang; Ruy M Ribeiro; John R Mascola; Mark G Lewis; Gabriela Stiegler; Hermann Katinger; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Authors:  Lifei Yang; Yufeng Song; Xiaomin Li; Xiaoxing Huang; Jingjing Liu; Heng Ding; Ping Zhu; Paul Zhou
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

5.  Human immunodeficiency virus-like particles activate multiple types of immune cells.

Authors:  Gangadhara Sailaja; Ioanna Skountzou; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2007-02-05       Impact factor: 3.616

6.  Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.

Authors:  Ioanna Skountzou; Fu-Shi Quan; Sailaja Gangadhara; Ling Ye; Andrei Vzorov; Periasamy Selvaraj; Joshy Jacob; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

7.  Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.

Authors:  Fu-Shi Quan; Gangadhara Sailaja; Ioanna Skountzou; Chunzi Huang; Andrei Vzorov; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

8.  Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Lei Pan; Zhigao Bu; Richard W Compans; Huizhong Zhang; Chinglai Yang
Journal:  J Biomed Biotechnol       Date:  2010-05-25

Review 9.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.